

Accepted Manuscript

HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches

Nilanjan Adhikari, Sk Abdul Amin, Prakruti Trivedi, Tarun Jha, Balaram Ghosh



PII: S0223-5234(18)30753-0

DOI: [10.1016/j.ejmech.2018.08.081](https://doi.org/10.1016/j.ejmech.2018.08.081)

Reference: EJMECH 10692

To appear in: *European Journal of Medicinal Chemistry*


Received Date: 3 May 2018

Revised Date: 8 August 2018

Accepted Date: 27 August 2018

Please cite this article as: N. Adhikari, S.A. Amin, P. Trivedi, T. Jha, B. Ghosh, HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches, *European Journal of Medicinal Chemistry* (2018), doi: 10.1016/j.ejmech.2018.08.081.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Download English Version:

<https://daneshyari.com/en/article/11006223>

Download Persian Version:

<https://daneshyari.com/article/11006223>

[Daneshyari.com](https://daneshyari.com)